scholarly journals Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer

Oncotarget ◽  
2017 ◽  
Vol 9 (2) ◽  
pp. 2076-2085 ◽  
Author(s):  
Andreas W. Berger ◽  
Daniel Schwerdel ◽  
Thomas J. Ettrich ◽  
Alexander Hann ◽  
Stefan A. Schmidt ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Deep Sequencing ◽  
Circulating Tumor Dna ◽  
Metastatic Pancreatic Cancer ◽  
Targeted Deep Sequencing ◽  
Tumor Dna

scholarly journals Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Gahee Park ◽  
Joo Kyung Park ◽  
Dae-Soon Son ◽  
Seung-Ho Shin ◽  
Yeon Jeong Kim ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Deep Sequencing ◽  
Circulating Tumor Dna ◽  
Targeted Deep Sequencing ◽  
Tumor Dna

scholarly journals Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Gabriella Cirmena ◽  
Anna Garuti ◽  
Marilena De Mariano ◽  
Simona Coco ◽  
Lorenzo Ferrando ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Deep Sequencing ◽  
Circulating Tumor Dna ◽  
Clinical Relapse ◽  
Breast Cancer Patients ◽  
Targeted Deep Sequencing ◽  
Tumor Dna

In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, there is an unmet need for noninvasive predictive biomarkers of response. The analysis of circulating tumor DNA (ctDNA) in particular has been the object of several reports, but few of them have studied the applicability of tagged targeted deep sequencing (tTDS) to clinical practice and its performance compared with droplet digital PCR (ddPCR). Here, we present the first results from an ongoing study involving a prospectively accrued, monocentric cohort of patients affected by invasive breast cancer, undergoing neoadjuvant chemotherapy followed by surgery with curative intent as per clinical practice. A pretreatment tumor biopsy and plasma samples were collected before and during treatment, after surgery, and every six months henceforth or until relapse, whichever came first. Pretreatment biopsies were sequenced with a 409-gene massive parallel sequencing (MPS) panel, allowing the identification of target mutations and their research in plasma by tTDS and ddPCR as a complementary approach. Using tTDS, we demonstrated the presence of at least one deleterious mutation in all the relapsed cases we studied (n = 4), with an average lead time of six months before clinical relapse. The association with ddPCR was suboptimal, and only one relapsed patient could be identified with such method. tTDS shows potential as an early noninvasive method for the detection of MRD in BC patients.

scholarly journals Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yeon Jeong Kim ◽  
Yumi Kang ◽  
Jun Seop Kim ◽  
Hyun Hwan Sung ◽  
Hwang Gyun Jeon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Deep Sequencing ◽  
Immune Checkpoint ◽  
Circulating Tumor Dna ◽  
First Line ◽  
Primary Tumors ◽  
Predictive Role ◽  
Targeted Deep Sequencing ◽  
Tumor Dna

AbstractWe evaluated the predictive role of circulating tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint blockades (ICB). To determine the feasibility of ctDNA detection in our panel encompassing 40 genes, we collected 10 ml of blood from 20 patients at the time of radical nephrectomy. We analyzed somatic mutations in primary tumors and ctDNA samples from these patients. We finally collected 10 ml of blood before and after 1 month of treatment, respectively, from four patients with mRCC who received first-line ICB treatment. Variants were detected in primary tumors of 15 patients (75%) and ctDNA was detected in the plasma of 9 patients (45%). We examined the predictive role of ctDNA in four patients who received first-line ICB therapy. In two patients showing partial response, ctDNA levels decreased after 1 month of ICB treatment. However, in one patient who showed disease progression, ctDNA levels increased after 1 month of ICB treatment. Taken together, ctDNA detection in plasma by targeted deep sequencing was feasible in patients with RCC. Moreover, the levels of ctDNA could be an early predictor of treatment response in patients with mRCC who receive ICB therapy.

scholarly journals Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing

2020 ◽  
Vol 22 (7) ◽  
pp. 860-870
Author(s):  
Zhenghao Cai ◽  
Zhenxin Wang ◽  
Chenglin Liu ◽  
Dongtao Shi ◽  
Dapeng Li ◽  
...  
Keyword(s):  
Microsatellite Instability ◽  
Deep Sequencing ◽  
Circulating Tumor Dna ◽  
Targeted Deep Sequencing ◽  
Tumor Dna

scholarly journals Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer

2016 ◽  
Vol 62 (11) ◽  
pp. 1482-1491 ◽  
Author(s):  
Nora Brychta ◽  
Thomas Krahn ◽  
Oliver von Ahsen
Keyword(s):  
Pancreatic Cancer ◽  
Early Stage ◽  
Digital Pcr ◽  
Circulating Tumor Dna ◽  
Surgical Removal ◽  
Plasma Samples ◽  
Kras Mutations ◽  
Detection Rates ◽  
Early Stages ◽  
Tumor Dna

Abstract BACKGROUND Since surgical removal remains the only cure for pancreatic cancer, early detection is of utmost importance. Circulating biomarkers have potential as diagnostic tool for pancreatic cancer, which typically causes clinical symptoms only in advanced stage. Because of their high prevalence in pancreatic cancer, KRAS proto-oncogene, GTPase [KRAS (previous name: Kirsten rat sarcoma viral oncogene homolog)] mutations may be used to identify tumor-derived circulating plasma DNA. Here we tested the diagnostic sensitivity of chip based digital PCR for the detection of KRAS mutations in circulating tumor DNA (ctDNA) in early stage pancreatic cancer. METHODS We analyzed matched plasma (2 mL) and tumor samples from 50 patients with pancreatic cancer. Early stages (I and II) were predominant (41/50) in this cohort. DNA was extracted from tumor and plasma samples and tested for the common codon 12 mutations G12D, G12V, and G12C by chip-based digital PCR. RESULTS We identified KRAS mutations in 72% of the tumors. 44% of the tumors were positive for G12D, 20% for G12V, and 10% for G12C. One tumor was positive for G12D and G12V. Analysis of the mutations in matched plasma samples revealed detection rates of 36% for G12D, 50% for G12V, and 0% for G12C. The detection appeared to be correlated with total number of tumor cells in the primary tumor. No KRAS mutations were detected in 20 samples of healthy control plasma. CONCLUSIONS Our results support further evaluation of tumor specific mutations as early diagnostic biomarkers using plasma samples as liquid biopsy.

Sign in / Sign up

Export Citation Format

Share Document